Jiangsu Hengrui Pharmaceuticals (600276.SH): Clinical research on the combined use of SHR-1826 with other drugs for injection has been approved.
Jiangsu Hengrui Medicine Co., Ltd. (600276.SH) announced that its subsidiaries, Suzhou Shengdiya Biopharmaceutical Co., Ltd. and Shanghai Shengdi...
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiary Suzhou Shengdiya Biopharmaceutical Co., Ltd. and Shanghai Shengdi Pharmaceuticals Co., Ltd. have received approval from the National Medical Products Administration for the clinical trial of injection SHR-1826, Adebril monoclonal antibody injection, and Bevacizumab monoclonal antibody injection. The companies will soon begin a multicenter, open-label phase Ib/II clinical study to evaluate the safety, tolerability, and effectiveness of injection SHR-1826 in combination with other anti-tumor treatments in patients with solid tumors.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
